Table 1:
Favored diagnosis, diagnostic confidence, and treatment recommendation before obtaining (pre-test) and after review (post-test) of PRAME IHC.1 Pre-test and post-test columns assess percentages of cases within a category overall (not pairwise changes between pre- and post- test results for a given individual case).
| Characteristic | Pre-test | Post-test | p value* |
|---|---|---|---|
| Diagnosis 2 | 0.6209 | ||
| Benign | 5/56 (8.9%) | 6/56 (10.7%) | |
| Indeterminate | 35/56 (66.1%) | 32/56 (57.1%) | |
| Malignant (in situ or invasive, with or without an associated nevus) | 15/56 (25.0%) | 18/56 (32.1%) | |
| Not stated | 11 cases (excluded) | ||
| Confidence | <0.0001 | ||
| Very unsure | 0/67 (0%) | 0/67 (0%) | |
| Unsure | 5/67 (7.5%) | 0/67 (0%) | |
| Somewhat unsure | 19/67 (28.4%) | 5/67 (7.5%) | |
| Neutral | 3/67 (4.5%) | 3/67 (4.5%) | |
| Somewhat confident | 26/67 (38.8%) | 22/67 (33.8%) | |
| Confident | 14/67 (20.9%) | 31/67 (46.3%) | |
| Very confident | 0/67 (0%) | 6/67 (9.0%) | |
| Not stated | 0 cases | ||
| Treatment recommendation 3 | 1.0000 | ||
| No further treatment necessary OR | 18/63 (28.6%) | 18/63 (28.6%) | |
| Close clinical surveillance | |||
| Excision with wide margin OR | 45/63 (71.4%) | 45/63 (71.4%) | |
| Wide local following MIS or melanoma guidelines OR | |||
| Sentinel lymph node biopsy and/or evaluation for metastasis | |||
| Not stated | 4 cases (excluded) | ||
1
Excluded cases that did not have both pre- and post-test survey answers.
2
Excluded cases that did not state preferred diagnosis.
3
Excluded cases that did not state treatment recommendation.
*
Chi square test was used to obtain p values while Fisher’s Exact Test was used when one of the incidences was less than 5.